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Identification and clinical annotation of risk alleles is
critical for young people with sarcoma for several rea-
sons. The mutated gene can be passed onto the next
generation affecting reproductive choices. In addition,
the risk of a second malignancy appears to be markedly
increased in some patients. Thirdly, the risk to other
relatives, parents and siblings may vary from 50% to an
unquantifiable risk. Finally, ionizing radiation increases
cancer risk synergistically in the presence of mutations
in sarcoma genes such as Rb and TP53 and diagnostic
and therapeutic radiation is modifiable in high risk indi-
viduals provided such mutations are identified.
The primary aim of this project will be seeking to
establish whether the detection of pathogenic germline
TP53 mutations in adult sarcoma patients can improve
outcomes through tailored clinical management. These
patients have been recruited through the International
Sarcoma Kindred Study (ISKS). This project will have
access to the ISKS biospecimens, pedigree data, genetic
information and data associated with clinical outcomes.
The ISKS currently has 450 adult sarcoma probands,
with recruitment on going. To date, sequencing has
already been performed on 272 of these probands, in
which 12 pathogenic mutations have been detected (4%).
Index cases with an identified pathogenic TP53 muta-
tion and their families will be systematically followed up
to ascertain outcomes and to recruit further family
members. The genetic status of this cohort will be col-
lated with their clinical characteristics through examina-
tion of medical records and family history through
pedigree data. The clinical outcomes of the identified
pathogenic TP53 mutation carriers and treatments given
will be documented and compared against affected non-
mutation carriers using a pseudo case-control study
design to assess how the effects of treatment combine
with mutation status.
A further aim of this project will be to conduct ana-
lyses nested within the whole ISKS cohort to seek to
establish the pathogenicity of unclassified variants that
have been detected so far in the ISKS cohort. This ana-
lysis will be twofold with the first part of the analysis
being conducted with novel variants that have not yet
been previously described. Once these variants are clas-
sified using an integrated evaluation approach, they will
be examined alongside other variants detected in the
cohort that have previously been described but where
the magnitude of their effect on the risk of sarcoma has
not yet been defined. A case-control study will then be
conducted, which will be seeking to establish whether
these variants are found at a higher frequency in sar-
coma patients than the general population, thus imply-
ing an association with sarcoma. Based on this
information, these variants will then be graded accord-
ing to the guidelines recommended by the IARC
Unclassified Genetic Variants Working Group to guide
clinical management for the different variants.
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